The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

(RTTNews) - Swiss drugmaker Novartis AG agreed to pay $245 million to settle an antitrust litigation for allegedly attempting to delay the launch of generic versions of its Exforge blood-pressure ...

The lawsuit alleges that as a result of a 2011 agreement between Novartis and Endo's Par, the plaintiffs paid higher for brand and generic Exforge than they otherwise would have been. (Novartis) ...

Novartis has said it will pay $245 million to resolve civil litigation in the US, which accuses it of a 'pay for delay' scheme involving generics of its high blood pressure therapy Exforge. The case ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. Exforge HCT contains the active ingredients Amlodipine Besilate, ...

(Reuters) - Swiss drugmaker Novartis AG has agreed to pay $30 million to settle claims by health plans and consumers that it schemed to delay the U.S. launch of generic competition for its Exforge ...

Deal is part of $245 million package announced last year Novartis, Endo unit accused of conspiring to keep competitors out Feb 23 (Reuters) - Swiss drugmaker Novartis AG has agreed to pay $30 million ...